ANNX

NASDAQ 已收盘

Annexon

3.41 USD
▼-0.11-3.12%
盘后 3.39 -0.59%
2026-11-19
市值
$591.37M
市盈率
—
EPS
-1.03
股息率
—
52 周区间
3.36 – 7.18
成交量
3.19M
Beta
1.44
目标价
17.00
52W 低 3.3652W 高 7.18
价格走势

公司简介

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase...